Getinge B stock holds close to new 52-week high as Nordea cuts rating after rally
Published on 08/31/2026 at 13:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Getinge B (SE0000202624) stock is trading close to a fresh 52-week high at the latest Nasdaq Stockholm close of 247.40 SEK on August 28, 2026, following a double-digit gain since the start of the year and a strong recent rally in the Swedish medtech name. Per a same-day analyst update published on August 31, 2026, the share advance has prompted a rating cut to hold, even as the fair value estimate is raised.
Nordea downgrade caps a strong share run
According to an analyst note reported on August 31, 2026, Getinge has been downgraded from buy to hold, with the fair value estimate increased to 260 SEK from 218 SEK, reflecting a more cautious stance on upside after the recent rally. The analyst report indicates that at the latest closing price of 247.40 SEK on August 28, 2026, the shares trade only 5.1 percent below the new 260 SEK target, while they stand 13.07 percent above the level at the start of 2026.
Consensus figures compiled in the same overview show a current average target price of 237.90 SEK compared with the latest closing price of 247.40 SEK, implying that Getinge B is 3.84 percent above that average benchmark. The consensus snapshot also cites an accumulated recommendation stance with 10 analysts covering the stock, underscoring how the recent share performance has pushed the valuation beyond the prevailing average target.
Share performance and technical backdrop
The rally in Getinge B stock has recently driven the shares to a new 52-week high, reinforcing bullish technical signals for investors tracking the Swedish healthcare sector. Per a chart signal overview dated August 28, 2026, Getinge B recorded a new 52-week high at a price level of 246.30 SEK, with a three-month performance of 27.73 percent under the long strategy used in the analysis. The 52-week high signal places the latest closing price of 247.40 SEK marginally above that prior high, confirming the upward trend.
Alongside the 13.07 percent gain since the beginning of 2026, the same data set lists a five-day change of 0.81 percent as of August 28, 2026, which points to a more moderate short-term move after the strong multi-month run. The pattern suggests that Getinge B stock has transitioned from a steep catch-up phase into a period where incremental gains are smaller, a typical dynamic when a share approaches key technical resistance levels such as a 52-week high cluster around the mid-240s SEK.
For investors, the relationship between the current price, the new 260 SEK fair value estimate and the 237.90 SEK consensus target provides a quantitative frame for how positioning has shifted. With the downgrade to hold taking place even as the fair value is lifted by 42 SEK, or 19.3 percent, the message is that much of the anticipated improvement is now reflected in the share price, limiting risk-reward for new entrants at current levels.
Fundamental backdrop and valuation context
While the freshest figures available in the same-day analyst and technical overviews concentrate on price targets and performance metrics rather than detailed quarterly revenue or earnings numbers, the valuation context implied by the new 260 SEK fair value can still be interpreted. The increase from 218 SEK to 260 SEK indicates that on the analyst model, Getinge B merits a higher value based on updated assumptions for the medtech business, even if the rating cut suggests that the share price has caught up with those expectations faster than anticipated.
Historically, Getinge B has been regarded as a key player in Swedish-listed medical technology, and the move to a new 52-week high aligns with that narrative of gradual operational improvement and market confidence. However, the fact that the latest closing price is already above the average 237.90 SEK target and only a small discount to the 260 SEK fair value means that the valuation cushion has narrowed compared with earlier periods when the price traded significantly below both target levels.
The 13.07 percent year-to-date increase noted in the analyst snapshot further underlines this compression. Compared with the start of 2026, investors holding Getinge B have seen a double-digit gain, and when that gain is placed alongside the relatively modest gap to the raised target, it highlights that future upside now depends more heavily on incremental fundamental improvements or sector tailwinds rather than simple mean reversion from depressed levels.
Getinge B product spotlight
Getinge B is part of Getinge AB, a global medical technology group known for equipment and solutions that support acute care, surgical procedures and life science applications. A representative product category for the company is its advanced operating room technology, including integrated surgical tables and infection-control systems designed to improve patient safety and hospital efficiency. These solutions are typically sold to hospitals and healthcare systems worldwide, providing a recurring base of demand that feeds into the valuation metrics reflected in the latest analyst targets and consensus figures.
Shares trade close to recent highs
As of the most recent completed Nasdaq Stockholm trading session on August 28, 2026, Getinge B shares closed at 247.40 SEK, placing them very close to the cited 52-week high level around 246.30 SEK and modestly above the current average target of 237.90 SEK. The stock is listed on Nasdaq Stockholm in Swedish kronor, and the observed gain of 13.07 percent since the start of 2026 underlines how the combination of operational progress and medtech sector sentiment has supported the share price over the year so far.
Fact box
Company: Getinge AB
ISIN: SE0000202624
Ticker: GETI B
Exchange: Nasdaq Stockholm
Price (as of August 28, 2026, 6:00 p.m. CET): 247.40 SEK
Market cap: not specified in available data
Sector / Industry: Healthcare - Medical technology
Index membership: not specified in available data
